Jumo Health

Canaccord Genuity Advises Jumo Health, an Innovative Clinical Trial Solutions Platform Driving Better Health Outcomes Globally, on its Investment from Falfurrias Management Partners

Canaccord Genuity has advised Jumo Health, which develops creative, patient-centric educational solutions that improve health literacy to accelerate clinical trial enrollment and increase participant retention, on its investment from Falfurrias Management Partners, a Charlotte-based private equity firm focused on growth-oriented, middle-market businesses. 

Jumo Health develops age-appropriate, culturally relevant, and relatable educational resources for patients and caregivers. The company has experience serving diverse populations and covers more than 160 health topics across 80+ countries in 120+ languages. Jumo Health’s various digital, video, and print offerings use highly visual elements and research-backed health literacy strategies to ensure that everyone can understand and act upon complex medical information. This information is delivered through familiar mediums – from comic books and animation to virtual reality experiences and authentic documentary-style patient stories – all customized based on audience. Jumo Health collaborates globally with more than 180 advocacy groups and community organizations to promote access and to ensure unique patient experiences are accurately represented.

While clinical trials suffer from low enrollment, high dropout rates, and a startling lack of diverse representation, Jumo Health's solutions aim to remedy these critical industry problems. The company’s curriculum-based educational solutions ensure prospective clinical trial participants have information relevant to their age, gender, race, language, and socioeconomic status at every stage of their journey, from pre-consent trial awareness to ongoing trial engagement. The result is faster recruitment, longer retention, increased patient compliance, and greater overall trial success for sponsors.

Equity for this investment comes from Falfurrias Capital Partners V, an operationally-focused, lower middle-market private equity fund focused on investing in high-growth companies in the food manufacturing, industrial technology, and business services sectors, and builds on the firm's experience in marketing and communications. The team is comprised of investors and proven operators, as well as in-house resources across strategy and market insights, finance and integration, human capital, and technology. 

Adam Cossman, an executive advisor on the Falfurrias team with 25 years of pharmaceutical commercialization experience, will join Jumo's board of directors as Chairman. Alexander Jutkowitz, an executive in residence at Falfurrias and global content marketing and communications expert, and Jackie Kent, a pharmaceutical executive with nearly 30 years of clinical trial innovation experience, will also join the board of directors.

The Falfurrias investment will bring new resources and expertise to the Jumo Health team and is aimed at expanding the organization's core capabilities, enabling data-driven solutions, and widening patient engagement. Specifically, Falfurrias is energized by Jumo Health's commitment to improving access to clinical trials among traditionally underrepresented communities, many of whom have a deep-seated mistrust of the healthcare system due to historical inequities. Jumo Health has taken tangible steps to rebuild this trust by creating culturally sensitive materials and establishing a robust network of patient advocacy groups and more than 2,000 religious, social, government, and community-based organizations.